Sudeep Pharma Share Price Today: Pharma Stock Zooms 6% After Strong IPO Listing; What’s Next For Investors?

Sudeep Pharma Share Price Today: Shares of Gujarat-based Sudeep Pharma rallied during intraday trade, after making a strong IPO listing on Friday. Sudeep Pharma's initial public offering (IPO) listed at a 24% premium on NSE and BSE. The pharma stock continued its upside momentum post listing.

Sudeep Pharma Share Price Today

Sudeep Pharma shares were trading 3.96% higher at Rs 763.05 per share on BSE at 10:45 am. The stock had surged over 6% and touched an intraday high of Rs 777 per share.

Sudeep Pharma IPO Listing Today

Sudeep Pharma shares are listed at a 24% premium in the Indian stock market on Friday. The IPO had fixed an upper price band of Rs 593 per share, and it listed at a price of Rs 733.95 per share on BSE. Sudeep Pharma stock was commanding a premium of 20.4% in the unlisted market. Its last IPO GMP today was recorded at Rs 121, indicating a listing at Rs 714, as per Chittorgarh.com.

Sudeep Pharma Share Price Rallies; What's Next For Investors?

The strong debut of Sudeep Pharma share IPO on Dalal street indicates robust investor confidence in its position as a leading player in the specialty pharma ingredients and excipients, according to experts.

"The enthusiasm around the IPO was evident well before listing day. In the unlisted market, Sudeep Pharma's shares were commanding a 20.40% premium, signalling strong demand from early investors. The company's ₹895 crore IPO saw overwhelming participation, being subscribed 93.72 times, with total bids crossing ₹58,700 crore across 29.86 lakh applications," noted Shivani Nyati, Head of Wealth at Swastika Investmart Ltd.

Its strong IPO listing is backed by its established presence in pharma and nutraceutical input materials, diversified product portfolio, long-term relationships with global pharma companies, etc.

"In the near term, investors may remain watchful of margin sustainability, raw material price swings, and competitive intensity in specialty chemicals and pharma ingredients. Given the strong listing pop, investors allocated shares may consider booking partial gains, while aggressive long-term investors bullish on the specialty pharma ingredient space may hold the remaining portion, with a disciplined stop-loss at Rs 690," explained Nyati.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions